Date: 2015-06-02
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: RedXPharma (UK)
Product: antibiotic designed to tackle Methicillin-Resistant Staphylococcus Aureus (MRSA)
Action
mechanism: antibiotic.
Disease: Methicillin-Resistant Staphylococcus Aureus (MRSA) infections
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On June 2, 2015, RedxPharma announced that it has reached pre-clinical development stage with a new anti-infective compound designed to tackle Methicillin-Resistant Staphylococcus Aureus (MRSA), the bacterium that causes potentially lethal infections in humans. The discovery is a significant milestone for Redx\'s commercial partnership with the NHS, working with The Royal Liverpool and Broadgreen University Hospitals Trust. The new compound is a member of the first new potential class of antibiotics to emerge in a generation and will be the first to progress through the development pathway established between Redx and the Trust under the terms of their partnership. This collaboration, signed in September 2013, was formed to find new drugs to combat the growing threat of drug-resistant bacteria, including MRSA. Redx\'s compound demonstrates excellent oral efficacy and has the potential to be easily administered both in the wider community and in a hospital setting. This is in contrast to current treatment for MRSA, which typically requires in-hospital treatment with antibiotics available only in an injectable form. The next stage of development will see the compound undergo pre-clinical testing managed by Redx. Following this, the new candidate will go into clinical development at the Royal Liverpool University Hospital, where it will be tested in humans at the Covance-Royal Liverpool University Hospital Clinical Research Unit. Once clinical proof of concept is reached, Redx will be responsible for the onward licensing of the candidate drug to a pharmaceutical partner for further development and commercialisation.
